Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.

MLA

Reliquet, V., et al. “Long-Term Assessment of Nevirapine-Containing Highly Active Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients: 3-Year Follow-up of the VIRGO Study.” HIV Medicine, vol. 7, no. 7, Oct. 2006, pp. 431–36. EBSCOhost, https://doi.org/10.1111/j.1468-1293.2006.00402.x.

APA

Reliquet, V., Allavena, C., François-Brunet, C., Perré, P., Bellein, V., Garré, M., May, T., Souala, F., Besnier, J.-M., & Raffi, F. (2006). Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Medicine, 7(7), 431–436. https://doi.org/10.1111/j.1468-1293.2006.00402.x

Chicago

Reliquet, V, C Allavena, C François-Brunet, P Perré, V Bellein, M Garré, T May, F Souala, J-M Besnier, and F Raffi. 2006. “Long-Term Assessment of Nevirapine-Containing Highly Active Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients: 3-Year Follow-up of the VIRGO Study.” HIV Medicine 7 (7): 431–36. doi:10.1111/j.1468-1293.2006.00402.x.